secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001437749-23-022875
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Q2 net loss $2.2M ($0.16/shr); camsirubicin at 5th dose level
---------------------------------------------------------------------

- Net loss of $2.2M ($0.16/shr) vs $2.8M ($0.22/shr) in Q2 2022.
- Cash and short-term investments $10.2M; cash runway through Sep 2024; needs more capital within 12 mos.
- Camsirubicin Phase 1b at 650 mg/m²; two patients showed 18% and 20% tumor reduction; no cardiotoxicity.
- MNPR-101 radiopharma advancing toward first-in-human studies potentially by end of 2023.
- R&D expenses decreased to $1.6M from $2.1M; G&A slightly up to $0.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/0001437749-23-022875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/mnpr20230808_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-022875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer